Medication-overuse headache

Current Pain and Headache Reports

Volumn 9, Issue 6, 2005, Pages 430-435

  Pageler, Lutz ^b   Savidou, Irini ^b   Limmroth, Volker ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CLONIDINE; DIPYRONE; ERGOT DERIVATIVE; ERGOTAMINE DERIVATIVE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RIZATRIPTAN; SUMATRIPTAN; TIZANIDINE; ZOLMITRIPTAN;

CLINICAL FEATURE; CLINICAL TRIAL; CLUSTER HEADACHE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; FLUID THERAPY; HUMAN; HYPOTENSION; META ANALYSIS; MIGRAINE; NAUSEA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TACHYCARDIA; TENSION HEADACHE; VOMITING;

EID: 28944437861     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-005-0023-6     Document Type: Review

References (41)

1. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988, 8(suppl 7):1-96.
2. Headache Classification Committee of the International Headache Society: The International Classification of Headache Disorders. Cephalalgia 2004, 24(suppl 1):1-150.
3. Silberstein SD, Olesen J, Bousser MG, et al.: The International Classification of Headache Disorders, edn 2 (ICHD-II): revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005, 25:460-465.
4. Schwarz A, Farber U, Glaeske G, et al.: Daten zu analgetikakonsum und analgetikanephropathie in der aundesrepublik. Effentliches Gesundheitswesen 1985, 47:298-300.
5. Gutzwiller F, Zemp E: Der analgetikakonsum in der bevölkerung und sociooekonomische aspeke des analgetikaabusus. In Das Analgetikasyndrom. Edited by Mihatsch MJ. Stuttgart: Thieme; 1986:197-205.
6. Eggen AE: The Tromso Study: frequency and predicting factors of analgesic drug use in a free-living population (12-56 years). J Clin Epidemiol 1993, 46:1297-1304.
7. Zwart JA, Dyb G, Hagen K, et al.: Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003, 61:160-164.
8. Williams D, Cahill T, Dowson A, et al.: Usage of triptans among migraine patients: an audit in nine GP practices. Curr Med Res Opin 2002, 18:1-9.
9. Gaist D, Andersen M, Aarup AL, et al.: Use of sumatriptan in Denmark in 1994-1995: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997, 43:429-433.
10. Gaist D, Tsiropoulos I, Sindrup SH, et al.: Inappropriate use of sumatriptan: population-based register and interview study. BMJ 1998, 316:1352-1353.
11. Gaist D, Hallas J, Sindrup SH, Gram LF: Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996, 50:161-165.
12. Katsarava Z, Schneeweiss S, Kurth T, et al.: Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004, 62:788-790.
13. Lanteri-Minet M, Auray JP, El Hasnaoui A, et al.: Prevalence and description of chronic daily headache in the general population in France. Pain 2003, 102:143-149.
14. Castillo J, Munoz P, Guitera V, Pascual J: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190-196.
15. Celentano DD, Stewart WF, Lipton RB, Reed ML: Medication use and disability among migraineurs: a national probability sample survey. Headache 1992, 32:223-228.
16. Dowson AJ: Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2003, 43:14-18.
17. Hagen K, Vatten L, Stovner LJ, et al.: Low socioeconomic status is associated with increased risk of frequent headache: a prospective study of 22,718 adults in Norway. Cephalalgia 2002, 22:672-679.
18. Wang SJ, Fuh JL, Lu SR, et al.: Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000, 54:314-319.
19. Lu SR, Fuh JL, Chen WT, et al.: Chronic daily headache in Taipei, Taiwan: prevalence, follow-up, and outcome predictors. Cephalalgia 2001, 21:980-986.
20. Hershey AD: Chronic daily headaches in children. Expert Opin Pharmacother 2003, 4:485-491.
21. Hering-Hanit R, Gadoth N, Cohen A, Horev Z: Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J Child Neurol 2001, 16:448-449.
22. Symon DN: Twelve cases of analgesic headache. Arch Dis Child 1998, 78:555-556.
23. Diener H, Dahlöf C: Headache associated with chronic use of substances. In The Headaches, edn 2. Edited by Olesen J, Tfelt-Hansen P, Welch K. Philadelphia: Lippincott, Williams & Wilkins; 1999:871-878.
24. Kaube H, May A, Diener H, Pfaffenrath V: Sumatriptan. Br Med J 1994, 308:1573-1574.
25. Limmroth V, Kazarawa Z, Fritsche G, Diener HC: Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 1999, 353:378.
26. Limmroth V, Katsarava Z, Fritsche G, et al.: Features of medication-overuse headache following overuse of different acute headache drugs. Neurology 2002, 59:1011-1014.
27. Bahra A, Walsh M, Menon S, Goadshy PJ: Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003, 43:179-190.
28. Feinstein AR, Heinemann LA, Dalessio D, et al.: Do caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000, 68:457-467.
29. Katsarava Z, Fritsche G, Muessig M, et al.: Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001, 57:1694-1698.
30. Saucier C, Morris SJ, Albert PR: Endogenous serotonin-2A and -2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium: desensitization and down-regulation by serotonin. Biochem Pharmacol 1998, 56:1347-1357.
31. Krymchantowski AV, Barbosa JS: Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000, 20:107-113.
32. Pageler L, Katsarava Z, Diener H, Limmroth V: Prednisone in the treatment of medication-withdrawal headache following medication-overuse headache: a placebo-controlled, double-blind, and randomized pilot study. Neurology 2005, 64(suppl 1):A423.
33. Smith TR: Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002, 42:175-177.
34. Mathew NT: Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 1987, 27:130-133.
35. Diener HC, Haab J, Peters C, et al.: Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 1991, 31:205-209.
36. Haag G, Baar H, Grotemeyer KH, et al.: [Prophylaxis and treatment of drug-induced persistent headache: therapy recommendation of the German Society for Migraine and Headache]. Schmerz 1999, 13:52-57.
37. Katsarava Z, Limmroth V, Finke M, et al.: Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003, 60:1682-1683.
38. Tribl GG, Schnider P, Wober C, et al.: Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia 2001, 21691-696.
39. Fritsche G, Eberl A, Katsarava Z, et al.: Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001, 45:229-235.
40. Katsarava Z, Muessig M, Dzagnidze A, et al.: Medication-overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005, 25:12-15.
41. Dowson AJ, Lipscombe S, Sender J, et al.: New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002, 18:414-439.